ProQR Therapeutics NV (PRQR) Share Price

SGMO 2.0 will see by the time anything gets to market its 10 years roughly still preclinical

Added a few more today flush with cash after the tax man has been dealt with. I just hope this doesn't see .50 Like Century Therapeutics one of the founders of CRSP is the CEO and Tim Walbert is on there board go figure!

500k shares will see wait and see where she goes before I add another 500k shares.

$PRQR

Bar coding down to $1.00 level then will fight for listing that's where this is going reminds me SGMO big partnerships the tech becomes outdated problem is PRQR hasn't even started a Phase 1 trial 10 years away from commercial product they failed in the clinic before history usually repeats itself ]



Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events

Advertise
About Us

Home

Biotech
Research
Medtech
CRO
Special Reports
Trending Topics
Fierce 50

Resources

Events
Subscribe

ProQR shares plummet as eye disease treatment flops phase 2/3 pediatric trial shares drop over 75%

$PRQR

https://fintel.io/i/van-herk-investments

% ?Ownership
File Date

Form

Security


Prev
Shares

Current
Shares

?Shares %

% Ownership

% ?Ownership
2025-02-14 13G/A PRQR / ProQR Therapeutics N.V. 8,170,254 11,461,995 40.29 10.90 7.92
2024-04-26 13G DMTKQ / DermTech, Inc. 1,628,057 1,778,057 9.21 5.10 6.25

DMTKQ is three cent stock Wowza

$PRQR

ProQR shares plummet as eye disease treatment flops ...
Fierce Biotech
https://www.fiercebiotech.com › biotech › proqr-treatm...
Feb 11, 2022 — ProQR's treatment for a congenital eye disease in children failed to improve vision and mobility, a tough pill to swallow that Wall Street ...
Missing: prqr ?| Show results with: prqr

ProQR to Cut 30% of Workforce, CSO Following ...
BioSpace
https://www.biospace.com › News › Drug Development
Apr 13, 2022 — In February, ProQR reported that Phase II/III clinical trials of sepofarsen failed to meet both primary and secondary endpoints. Sepofarsen is a ...
Missing: prqr ?| Show results with: prqr

ProQR eye drug comes up short in key study, surprising ...
BioPharma Dive
https://www.biopharmadive.com › news › proqr-lca-ey...
Feb 11, 2022 — The biotech's treatment did not improve vision in the Phase 2/3 trial, a significant setback that sent shares down by 75%.


$PRQR

All indications are pre-clinical I hope they sell it sooner than later these guys really move slow. Lily was a strategic partner SCYX

PRQR Phase 1 data by year end probably end up being early 2026 to be realistic this company has lagged a bit. Be patient and add the dips.

SCYNEXIS is a biotechnology company focused on developing innovative treatments for serious fungal infections, and they have a collaboration with Eli Lilly, specifically around the development of fungerp technology for treating fungal infections. PRQR is a risky bet Lily partnered with SCYX 35 million market cap and it has become a dud-nothing is a sure thing here!

up tp 430k shares

Average price 1.80


$PRQR

Added 207k shares today up too almost 390k more to go keep selling me your shares~

$PRQR

PRQR is an Eli Lilly oligonucleotide RNA Editing Platform 17.1% ownership New Next generation Platform with huge indications like obesity and cardiovascular diseases Lily will be able to manufacture these drugs for them. Never Seen Lily own so much of a small cap company and make milestone payments on them so soon. These Milestones so far will reach close to 4 Billion dollars and payments have commenced.


Eli Lilly made a 25M Royalty payment in 2024 vs. $3.9B in potential milestone payments so far 5 more indications lily totaling 15 indications and cash runway for over the next 2.5 years. “Lilly” has 95 appearances in their annual report.

PRQR has 2 founders plus chief CMO from Analyam the leader in RNAI 31 Billion company
1. Martin Maier, PhD


Martin Maier, PhD, joined our board in 2024. Dr. Maier currently serves as Senior Vice President, Oncology at Alnylam Pharmaceuticals. Dr. Maier joined Alnylam in 2006 and has contributed to the development of lipid nanoparticles and GalNAc conjugates, two clinically validated platforms for siRNA delivery, and the advancement of multiple therapeutic programs to development, which has resulted in the approval of five RNAi therapeutic to date.

2.Phillip D. Zamore, PhD

Phillip is a Howard Hughes Medical Institute Investigator, Gretchen Stone Cook Chair of Biomedical Sciences, Professor of Biochemistry and Molecular Pharmacology, and Chair of the RNA Therapeutics Institute at the University of Massachusetts Medical School. He is also a co-founder of Alnylam Pharmaceuticals

3.John Maraganore, PhD, joined as a strategic advisor to our Board in March 2022. He served as the founding Chief Executive Officer and a Director of Alnylam from 2002 to 2021, where he built the company from early platform research on RNA interference through global approval and commercialization of the first four RNAi therapeutic medicines, ONPATTRO®, GIVLAARI®, OXLUMO®, and Leqvio®. At Alnylam, he also led the company’s value creation strategy, building $ 25.0 billion in market capitalization

No other company has all key executives of Alnylam connected to any team in Biotech.

lastly

A. Peter Beal, PhD

Peter was appointed as ProQR's Chief ADAR Scientist in December 2024. Peter is a Professor in the Department of Chemistry at the University of California at Davis and Director of the NIH-funded UC Davis Chemical Biology Graduate Program. For over 25 years, work in the Beal laboratory has advanced understanding of the structures and mechanism of action for the ADAR enzymes responsible for adenosine to inosine RNA editing in humans. In addition, his group has led in the development of structure-guided methods for optimizing chemically modified oligonucleotides for recruitment of RNA-binding proteins including ADARs. Beal teaches organic chemistry at the undergraduate level and several classes in nucleic acids chemistry and chemical biology at the graduate level. He has authored over 100 peer-reviewed publications in the field of RNA chemical biology and mentored over 50 Ph.D. and M.S. degree students.



I will be buying up shares up to $2.00 today.

My thoughts are hold for 2 years you have a high probability of success maximizing profits and a buyout from LILY or Alnylam Pharmaceuticals. for 1.5-2 Billion similar to Roche buying Poseida for a total of 1.5 Billion last year early stage gene editing company.

PRQR has close to 30 Indications in their pipeline 15 of them with ELI Lilly

$PRQR

54.36% owned by Institutions[ thats not including Eli Lilly & Van Herk thats another 27.2% =81.5%+ Insiders 14.5% 95% dirk haussecker north 2% M28 Capital 1%
98% of PRQR shares are accounted for
Adage Capital Partners GP L.L.C. 9.6M Dec 31, 2024 11.76% 16,707,967
Privium Fund Management B.V. 4.99M Dec 31, 2024 6.10% 8,675,001
Woodline Partners LP 3.56M Dec 31, 2024 4.35% 6,189,181
Affinity Asset Advisors, Llc 2.83M Dec 31, 2024 3.46% 4,915,500
Millennium Management Llc 2.83M Dec 31, 2024 3.46% 4,919,467
UBS Group AG 2.31M Dec 31, 2024 2.83% 4,019,487
Sio Capital Management, LLC 2.05M Dec 31, 2024 2.52% 3,574,991
Kynam Capital Management, LP 1.75M Dec 31, 2024 2.14% 3,045,000
Siren, L.L.C. 1.57M Dec 31, 2024 1.93% 2,740,500
DAFNA Capital Management, LLC 1.57M Dec 31, 2024 1.92% 2,727,556

Eli Lilly owns 16.1% check the filings if you don't believe me not included in institutional ownership Largest Pharma company in the world

Van Herk Investments B.V.owns 11.1% not included in institutional ownership (one of the largest real estate holders in Europe)
=81.6% roughly including Lilly & Van Herk
Insiders own 14.5%
96% of the shares are spoken for remember dirk haussecker owns 2% and M28 Capital owns over a million shares and Keeps adding shares.

There are no shares Floating around. If you can see the asymmetric upside here place your bets. I bought a chunk of the shares today and need another 863k shares.

WVE 1.6 Billion
PRQR 184 Million superior technology Patent protection Partnerships and Team

$PRQR

Dirk Haussecker RNA editing expert owns north of 2% of PRQR shares!

Disclosure: I own >2% of the company stock. This blog post is not meant as a stock recommendation, but to provide greater visibility and transparency of ProQR and ADAR RNA Editing. Dirk Haussecker

Eli Lilly owns 16.5% of the shares

I will build a million share core position here over the coming weeks!

$PRQR

Starting to Buy PRQR this morning this company is worth more than WVE

Eli Lilly owns close to 20% of the company and their funded through 2027 IP Patents = BULLET PROOF

they get bought by LLY or ALNY for 1.5-2 Billion in the next 24 months or less

IP is bullet proof for oligonucleotide editing space they will receive royalties from others in the space.

Only small cap with 100x if they decide not to sell their soon to be conglomerate funded through 2027 with Lily starting to pay them on 3.9 Billion partnership in place with PRQR

This reminds me of Horizon Therapeutics sold for 28 Billion and Stock price history for Horizon Therapeutics (HZNP). Highest end of day price: $119.91 USD on 2021-10-29. Lowest end of day price: $1.99 USD on 2013-03-04.

Similar Story PRQR CEO has a son with a rare disease like Horizons PRQR is backed by the most powerful biotech company in the world LLY & the king of RNAI Alnylam what a great fit PRQR would be for either powerhouse.

RNA editing for 30 Indications

All founders from ALNY on the PRQR board

$PRQR

Sold last week after management seems dis-organized and European companies are risky and these guys are so far early in their clinical development.

$PRQR

CEO says to expect updates of what LLY has been up to in RNA editing in 2025.

LLY participate in offering on top of 3.5bn deal... at 3.50 strike
i believe 5$ next

https://www.globenewswire.com/news-release/2024/10/23/2967435/33039/en/ProQR-Prices-75-Million-Underwritten-Public-Offering-and-Concurrent-Private-Placement.html

Doubling my position here today!

Love this technology and team

$PRQR

PRQR is WVE 2.0

Glad I loaded the day before the break out!

100k shares long Love the Lily connection and brain power from ALNY at PRQR very early pipeline buy out sooner than later.

Lily owns over 16% of PRQR

$PRQR

PRQR.........................https://stockcharts.com/h-sc/ui?s=PRQR&p=W&b=5&g=0&id=p86431144783

Now over 4 and still no offering after the stock doubled this week on the WVE RNA success. Believe 6$ coming.

Still has this deal with LLY:
https://finance.yahoo.com/news/eli-lilly-inks-another-rna-105803336.html

doubling down in 2022:
https://finance.yahoo.com/news/proqr-therapeutics-shares-soar-eli-135337366.html

PRQR............................https://stockcharts.com/h-sc/ui?s=PRQR&p=W&b=5&g=0&id=p86431144783

Looks interesting need to do more DD

may take a starter here soon.

$PRQR

PRQR under $3

the companies IR signals they are far from letting the LLY deal sour, 4bn in milestones, next payments are due soon.

LLY left none of their darligns behind so far,

PRQR under $2

PRQR under $2

PRQR under $2

added 2.01 hoping for love from LLY, 4bln in milestones.

PRQR.....................................https://stockcharts.com/h-sc/ui?s=PRQR&p=W&b=5&g=0&id=p86431144783

PRQR............................https://stockcharts.com/h-sc/ui?s=PRQR&p=W&b=5&g=0&id=p86431144783

PRQR under $2

PRQR under $2

$PRQR - 👆Up 7.3% Pre-Market/ Current Price $1.65
Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets

Nice rebound!

$0.4~

Ya....

Eli Lilly sends ProQR 35% higher after expanding RNA editing deal

https://seekingalpha.com/news/3919739-prqr-stock-surges-as-eli-lilly-expands-rna-editing-deal

$PRQR Strong break up the chart..on watch next week

https://stockcharts.com/c-sc/sc?s=PRQR&p=D&b=5&g=0&i=0&r=1668863394516

Time for a bounce … I hope :)

$4 is the lowest consensus I can find here:
https://etfdailynews.com/news/proqr-therapeutics-nasdaqprqr-pt-lowered-to-8-00/

What say you?

Also, when do we know it stopped dropping?

....looking for a 80 cent deadcat bounce?????

PRQR holding steady in market colapse odds are for up in 3 days.

PRQR 1.38 start.

ProQR Therapeutics SCHEDULE 13G 02/04/2022
Amended: It`s a boy!!!!!!!!! Really they only missed a 100,000 shares bought by Wellington Management Group LLP that is runs a lot of Vanguard and ETF funds.....
https://www.streetinsider.com/SEC+Filings/Form++SC+13GA+++ProQR+Therapeutics+N.V.++++++++++++++++Filed+by%3A+WELLINGTON+MANAGEMENT+GROUP+LLP/19559743.html

nm

Important area here for PRQR in the 8.40ish resistance. Hopefully we can get a volume surge.

Some Nov/Dec call options with $10 strike traded today.. time for the pps to get up there. Looking stable going into 2022. Q 1/2 will be big.

Im liking the setup. Come on PRQR, make the move. Bollinger says we’re close.

Lilly earnings tomorrow wonder if we get a mention

Investment Case On ProQR Therapeutics Gets More Enticing

Looks like the high 7’s are even better! Man somebody took the air out of this balloon today.

Murocman

Low $8’s is a great place to add, me thinks.